Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Farrokhi Moshai, L. Wemeau-Stervinou, N. Cigna, J. Marchal-Somme, V. Besnard, S. Brayer, A. Fabre, A. Mailleux, B. Crestani (Paris, France). Targeting the hedgehog/GLI pathway decreases bleomycin-induced lung fibrosis. Eur Respir J 2013; 42: Suppl. 57, 3329

Member's Comments

No comment yet.

Related content which might interest you: Regulation of autophagy in amiodarone induced pulmonary fibrosis Source: Annual Congress 2013 –The vulnerable patient and ageing cells Year: 2013 Thymosin beta4 protects mice from bleomycin-induced damage in the lung Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Arginase 1 contributes to fibrogenesis in the lungs of silica-challenge mice Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Resveratrol regulates ECM remodeling in lung fibrosis Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 A transient receptor potential melastin-2 deficiency significantly worsens the fibrotic response to bleomycin in mice Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Metalloproteases gene expression and remodeling of lung parenchyma fibers during the progression of elastase induced emphysema Source: International Congress 2014 – Mechanisms of COPD and inhalation injury Year: 2014 Collagen V activation and matrix extracellular remodeling mediated pulmonary fibrosis in experimental models of bleomycin and 3-5-di-tert-4-hidroxitoluene Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013 Inhalation of chlorine causes lung inflammation and airway hyperresponsiveness in a rat model of chemical-induced lung injury Source: International Congress 2015 – Inflammation and remodelling in lung disease Year: 2015 17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice via decreasing MCP-1 mRNA Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Comparison of expression of napsin A and surfactant protein D in bleomycin-induced pulmonary fibrosis mouse model Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Matrix metalloproteinase-2 is protective in bleomycin-induced pulmonary fibrosis Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 CD39 deficiency results in increased inflammation in an animal model of pulmonary fibrosis Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Protective effects of Dengzhanshengmai capsules on bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2014 – ILDs 3 Year: 2014 Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Promotion of lung cancer progression by COPD-like chronic inflammation in a mouse model Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 Olodaterol attenuates bleomycin induced lung fibrosis in mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Late Breaking Abstract - PRRX1 inhibition decreases fibrosis in the bleomycin-induced lung fibrosis model in mice Source: International Congress 2018 – Regenerative and anti-fibrotic approaches Year: 2018 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013